医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toyoda Gosei Invests in Genial Light, a Medical Device Development Startup

2021年03月30日 PM01:00
このエントリーをはてなブックマークに追加


 

KIYOSU, Japan

Toyoda Gosei Co., Ltd. (TOKYO:7282) has invested in Genial Light Co., Ltd., a startup that develops testing equipment and other devices for medical institutions, with the aim of promoting product development in the healthcare field.

In recent years, Toyoda Gosei has focused increasingly on innovations that exploit its core technologies in order to achieve sustainable growth during a time of great upheaval in the automotive industry. The company is pioneering new businesses and developing products in the healthcare and other fields for which there is rising social demand. Examples include the development of deep UV LEDs for bacterial and viral disinfection and e-Rubber, a new material that is promising for use as a flexible sensor.

Since its foundation in 2006, Genial Light has worked together with medical device manufacturers and applied its optical technologies to develop small inspection devices for international markets. This includes devices that provide highly accurate measurements of biological information, such as pulse and blood components, and devices that measure blood in patients’ urine and hemoglobin concentration while they are receiving dialysis.

Toyoda Gosei will integrate Genial Light’s expertise in the medical and healthcare business in accelerating practical application of products that contribute to a healthier and safer society.

Outline of Genial Light

Company name

Genial Light Co., Ltd.

Location

Taijuseimei Hamamatsu Building 8F, 145-1 Tokiwacho, Naka-ku, Hamamatsu, Shizuoka, Japan

CEO

Ryo Shimokita

Founded

November, 2006

Capital

223 million yen (as of February 28, 2021)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005188/en/

CONTACT

Toyoda Gosei Co., Ltd.

Contact: Takatomo Abe

inquiry@mail.toyoda-gosei.co.jp

同じカテゴリーの記事 

  • 日本天皇陛下和皇后出席2024年度日本奖颁奖典礼
  • Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions
  • ReNAgade Therapeutics宣布在ASGCT第27届年会上发表演讲
  • ReNAgade TherapeuticsがASGCT第27回年次総会でのプレゼンテーションの内容を発表
  • BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer